Key Points
- Insider sale: Emil Kuriakose sold 942 shares on April 1 at $52.75 for $49,690.50, reducing his stake by 0.88% to 105,673 shares (valued at about $5.57M).
- Earnings and analyst view: Terns reported Q results of ($0.24) EPS beating estimates of ($0.30), yet several firms have downgraded the stock and the consensus rating is "Hold" with an average target of $56.30.
- Market context: The stock is trading near its 52-week high (opened at $52.72, 52-week high $53.19), has a market cap of $6.08B, and is heavily institutionally owned (98.26%).
Terns Pharmaceuticals, Inc. (NASDAQ:TERN - Get Free Report) insider Emil Kuriakose sold 942 shares of Terns Pharmaceuticals stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total transaction of $49,690.50. Following the completion of the transaction, the insider directly owned 105,673 shares of the company's stock, valued at $5,574,250.75. This trade represents a 0.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Emil Kuriakose also recently made the following trade(s):
- On Friday, January 2nd, Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock. The stock was sold at an average price of $38.57, for a total transaction of $44,548.35.
Terns Pharmaceuticals Stock Down 0.1%
Shares of NASDAQ TERN opened at $52.72 on Friday. The firm's 50-day moving average price is $42.59 and its two-hundred day moving average price is $30.32. Terns Pharmaceuticals, Inc. has a 52-week low of $1.87 and a 52-week high of $53.19. The stock has a market capitalization of $6.08 billion, a P/E ratio of -51.18 and a beta of -0.37.
Terns Pharmaceuticals (NASDAQ:TERN - Get Free Report) last announced its quarterly earnings results on Thursday, April 2nd. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.30) by $0.06. As a group, equities research analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.
Analysts Set New Price Targets
TERN has been the topic of several analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Terns Pharmaceuticals in a research report on Friday, March 27th. HC Wainwright reissued a "neutral" rating and set a $53.00 price target (down from $60.00) on shares of Terns Pharmaceuticals in a report on Wednesday, March 25th. Truist Financial lowered shares of Terns Pharmaceuticals from a "buy" rating to a "hold" rating and lowered their price target for the stock from $56.00 to $53.00 in a research report on Tuesday. BMO Capital Markets downgraded shares of Terns Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, March 26th. Finally, Mizuho lowered shares of Terns Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, March 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $56.30.
Read Our Latest Research Report on TERN
Institutional Trading of Terns Pharmaceuticals
Several institutional investors have recently modified their holdings of the company. Cubist Systematic Strategies LLC grew its holdings in Terns Pharmaceuticals by 136.8% during the first quarter. Cubist Systematic Strategies LLC now owns 28,327 shares of the company's stock worth $78,000 after acquiring an additional 16,363 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Terns Pharmaceuticals in the 1st quarter valued at about $51,000. Goldman Sachs Group Inc. lifted its holdings in Terns Pharmaceuticals by 21.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 415,021 shares of the company's stock valued at $1,145,000 after acquiring an additional 71,971 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Terns Pharmaceuticals by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company's stock valued at $6,094,000 after purchasing an additional 59,145 shares in the last quarter. Finally, Intech Investment Management LLC grew its stake in shares of Terns Pharmaceuticals by 15.5% in the 2nd quarter. Intech Investment Management LLC now owns 46,121 shares of the company's stock worth $172,000 after purchasing an additional 6,199 shares during the last quarter. Institutional investors and hedge funds own 98.26% of the company's stock.
About Terns Pharmaceuticals
(
Get Free Report)
Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company's research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.
The company's pipeline features several candidates in various stages of preclinical and clinical evaluation.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
